BRIDGEWATER, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra(R) SoloSTAR(R ...

The approval of Apidra (R) for pediatric use is based upon a 26-week, phase III, open-label, active control study of Apidra (R) in comparison with insulin lispro in 572 children and adolescents (4 - ...

Apidra SoloSTAR (insulin glulisine [rDNA origin] injection, from sanofi-aventis), a prefilled disposable pen containing Apidra, is now available. Apidra SoloSTAR makes administration of insulin more ...

PARIS, June 25 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 ...

PARIS, Feb 26 (Reuters) - Sanofi-Aventis has won U.S. approval to market its Apidra Solostar injection pen which contains insulin to treat diabetes, the world's third-biggest drugmaker said on ...

Approval of APIDRA® gives a shot-in-the-arm to treatment of diabetes, especially in countries like the UAE where diabetes prevalence is among the highest in the world Sanofi-aventis announced ...

- First Randomized Controlled Trial to Show That Basal Plus Regimen Provides more Effective Glycemic Control with Less Hypoglycemia Than with Aspart Premixed Insulin "Comparison of 3 intensified ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients and health care professionals can expect a ...

More Americans with diabetes will get a break on their insulin costs in 2024. Sanofi is joining the nation's two other major insulin manufacturers in offering either price caps or savings programs ...

The FDA has approved Apidra SoloSTAR (insulin glulisine[rDNA origin] injection, from sanofi-aventis), a prefilled disposable pencontaining Apidra. Apidra SoloSTAR makes administration of insulin ...